Loading
A phase 1/2 trial of LRK-4189 escalation in advanced solid tumours, run by LARKSPUR BIOSCIENCES, INC., now recruiting.
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07498725 by LARKSPUR BIOSCIENCES, INC., with 120 participants planned, started 2026-07-07 and due to reach its primary completion in 2029-06. Interventions recorded: LRK-4189 escalation, LRK-4189 expansion, LRK-4189 optimization and Chemo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum agents, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/